Effect of teriparatide (rh-PTH 1–34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study

Akira Iwata 1,2*, Masahiro Kanayama 1, Fumihiro Oha 1, Tomoyuki Hashimoto 1 and Norimasa Iwasaki 2

Abstract

Background: Teriparatide (recombinant human parathyroid hormone 1–34) is increasingly used for the treatment of severe osteoporosis because it stimulates bone formation and may potentially enhance fracture healing. The objective of this study was to investigate the effects of teriparatide versus a bisphosphonate on radiographic outcomes in the treatment of osteoporotic vertebral compression fractures (OVCF).

Methods: A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed retrospectively. Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group). Except for these medications, the same treatment protocol was applied to both groups. The radiographic assessments included union status, vertebral kyphosis, and mid-vertebral body height. The rates of fracture site surgical intervention were also compared between the two groups. The mean follow-up period was 27 months (median 22.5, range 2 – 75 months).

Results: Cox regression analysis showed that TPD reduced the time-to-union (adjusted relative hazard ratio: 1.86, 95% CI: 1.21 – 2.83). The union rate at six months after treatment was 89% in the TPD group and 68% in the BP group; the surgical intervention rate was significantly higher in the TPD group (p = 0.026, adjusted odds ratio: 8.15, 95% CI: 2.02 – 43.33). The change in local kyphosis was 4.6° in the TPD group and 3.8° in the BP group (p = 0.495, paired t-test). The change of mid-vertebral body height was 4.4 mm in the TPD group and 3.4 mm in the BP group (p = 0.228, paired t-test). Fracture site surgical interventions were not required in the TPD group; however, two patients in the BP group eventually underwent surgical treatment for symptomatic non-union or vertebral collapse.

Conclusions: This retrospective study suggests that teriparatide may enhance fracture healing and improve the union rate in OVCF.

Keywords: Teriparatide, Recombinant human parathyroid hormone 1–34, Bisphosphonates, Union rate, Osteoporosis, Osteoporotic vertebral compression fracture
Background
Pharmaceutical agents play a major role in the treatment of osteoporosis. Bisphosphonates, which inhibit osteoclast activity and bone resorption, are the current first-line medications for osteoporosis [1]. The robust suppression of osteoclast activity may hinder bone remodeling and maturation in the fracture healing process [2]. Although this adverse effect on fracture healing might raise concerns, such potential effects on healing have not been clinically evidenced in a meta-analysis of prospective randomized trials [3] and a systematic review [4].

Teriparatide (TPD, recombinant human parathyroid hormone (PTH) 1–34), an osteogenic osteoporosis agent, has been used increasingly for patients with severe osteoporosis and at high risk of fractures. Intermittent systemic administration of PTH induces bone formation through stimulation of osteoblast proliferation [5], prevention of osteoblast apoptosis [6] and increased osteoblast activity [5, 7]. This pharmaceutical agent may potentially enhance fracture healing.

Failure of fracture healing in osteoporotic vertebral compression fracture (OVCF) leads to intractable back pain associated with non-union [8, 9] and delayed vertebral collapse, resulting in neurological deficits [10]. Percutaneous vertebral augmentation is a widely accepted treatment option for OVCF. In particular, balloon kyphoplasty (BKP) may correct vertebral body height and local kyphotic deformity [11]. However, the differences in pain control between patients who received non-surgical care and kyphoplasty treatment were diminished at 12 months because the non-surgical group improved over time, probably as a result of fracture healing [12, 13]. Differences in the eventual outcome of patients with OVCF depend greatly on the union status. To date, however, whether teriparatide may enhance OVCF healing remains unclear. The current retrospective comparative study aimed to investigate the effect of teriparatide versus bisphosphonate on radiographic outcomes in the non-operative treatment of OVCF and to determine whether teriparatide enhances OVCF fracture healing.

Methods
A total of 98 patients who underwent non-operative treatment for a single-level recent OVCF between April 2010 and March 2012 were reviewed retrospectively. Included were 12 males and 86 females with a mean age of 76.7 years (58 – 94 years). A recent OVCF was diagnosed using 1.5-tesla MRI when a signal change of the affected vertebra (low signal intensity on the T1-weighted image or high signal intensity in short inversion time recovery on the T2-weighted image) was observed. The bone mineral densities of the lumbar spine and femoral neck were measured before treatment using dual-energy X-ray absorptiometry (DXA; Delphi QDR System, Toyo Medic Company, Tokyo, Japan). Osteoporosis was defined by a DXA-measured lumbar spine or femoral neck bone mineral density below 70% of the young adult mean (YAM) (T-score less than −2.5) or 70-80% of YAM (T-score under −2.5 to −1.5) with a fragility-related fracture [14]. Patients with steroid-induced osteoporosis or those who underwent dialysis for chronic renal failure were excluded from the current investigation. The patients were divided into two treatment groups based on the medication used: 38 patients received teriparatide (TPD group) and 60 patients received a bisphosphonate (BP group). Background demographic data are listed in Table 1.

The TPD group received 20 micrograms of teriparatide administered by subcutaneous injection once daily. In the BP group, 35 mg of alendronate was orally administered once a week (the therapeutic dose of alendronate, 70 mg per week in the United States and Europe, is limited to 35 mg per week in Japan). The bisphosphonate group consisted of patients with OVCF who had been treated with alendronate in the same manner from 2006. The TPD group consisted of those who were treated using teriparatide after teriparatide became available in Japan. No patients in either group received calcium or vitamin D supplements. Except for TPD and BP administration, the same treatment protocol was applied to both groups. Patients were permitted to ambulate with a custom-made plastic orthosis during the first week of treatment. The mean follow-up period was 27 months (median 22.5, range 2 to 75 months). Fifteen patients in the TPD group and 10 patients in the BP group

| Table 1 Demographic data for the teriparatide group versus the bisphosphonate group |
|------------------------------------|-----------------|-----------------|---------|
| Age (years) (mean ± SD)            | TPD (n = 38)    | BP (n = 60)     | p-value |
| Gender (male:female)               | 75.5 ± 7.1      | 77.6 ± 8.0      | 0.205   |
| BMD at lumbar spine (g/cm²) (mean ± SD) | 0.709 ± 0.020  | 0.692 ± 0.019  | 0.561   |
| BMD at femoral neck (g/cm²) (mean ± SD)  | 0.520 ± 0.018  | 0.531 ± 0.015  | 0.655   |
| GFR (mL/min/1.73²)                 | 64.0 ± 3.2      | 65.1 ± 2.8      | 0.796   |
| Pre-existing VCF (present: not present) | 8.30            | 15.45          | 0.653   |
| Level of vertebral fracture (non-TLTL) | 17.21           | 18.42          | 0.138   |
| Posterior wall fracture (not injured/injured) | 16.22          | 28.32          | 0.658   |
| Prior bisphosphonate use (not used/used) | 17.21           | 42.18          | 0.021*  |

* p < 0.05, TPD teriparatide group, BP bisphosphonate group, SD standard deviation, BMD bone mineral density, GFR glomerular filtration rate, VCF vertebral compression fracture, TL thoracolumbar spine (T11-L2), non-TL non-thoracolumbar spine (T5-T10 or L3-L5)
completed follow-up within 6 months because radiographic union was achieved.

Union status and deformity of the fractured vertebra were assessed radiographically. Radiographic examinations were performed once a week during the first month of treatment, once a month until the third month, and once every three months subsequently until union was confirmed. Assessment at six months after treatment was based on the radiographs obtained at six months plus/minus one month. The parameters included union rate at six months and at the final follow-up after treatment, vertebral kyphosis and mid-vertebral body height. Three independent observers assessed radiographic union (two examiners performed the evaluations independently, and another examiner independently assessed the cases when the conclusions of the two observers differed). Non-union was diagnosed by the presence of a vertebral cleft or abnormal motion at the fractured vertebra on the flexion-extension radiographs. Notwithstanding evidence of a vertebral cleft, the presence of trabecular continuity or bridging of bone around the cleft were regarded as radiographic union (Fig. 1). The Kappa statistic of intraclass correlation coefficient was 0.787 (95% confidence interval: 0.674 – 0.901). The Kappa statistic of inter-rater reliability was 0.952 (95% confidence interval: 0.887 – 1.000). The rate of fracture site surgical intervention was also compared between the two groups.

Age and bone mineral density were compared as continuous variables using the unpaired t-test. Gender, prevalence of pre-existing vertebral fracture, rate of thoracolumbar (T11-L2) vertebral fracture, incidence of posterior wall fracture, rate of prior bisphosphonate use, and union status (presence or absence of radiographic union) were analyzed as categorical data using Fisher’s exact test. Mid-vertebral body height and kyphosis angle were compared pre- and post-treatment using the paired t-test. Progression of vertebral deformity was defined as >15% loss of vertebral body height or >10° of kyphosis progression [15]. The level of significance was defined as a p-value of less than 0.05. Statistical analyses were performed using JMP Pro 11 software (SAS Institute Inc., Cary, North Carolina, USA). Multivariate logistic regression analysis was used to evaluate associations between union status and demographic data including pharmaceutical agents. Multiple dichotomous variables included 1) age (<80 or ≥80 years), 2) gender (male or female), 3) lumbar spine bone mineral density (≤ −2.5 or > −2.5 SD), 4) fracture level (thoracolumbar (T11-L2) or non-thoracolumbar (T5-T10 or L3-L5)), 5) presence of pre-existing vertebral fracture (existent or non-existent), 6) incidence of posterior wall fracture (injured or not injured), 7) rate of past bisphosphonate use (used or not used), and 8) pharmaceutical agent (TPD or BP). Kaplan-Meier analysis was used to compare the time-to-union between the TPD and BP groups, and Cox regression analysis was used to examine the covariates for time-to-union.

**Results**

Kaplan-Meier survival analysis showed a significant difference in the time-to-union between the two groups (p < 0.001, log-rank test) (Fig. 2). Cox regression analysis showed an adjusted relative hazard for TPD versus BP use of 1.86 (95% C.I.: 1.21–2.83). The radiographic union rate was 89% (34/38 patients) in the TPD group versus 68% (41/60 patients) in the BP group at six months after treatment, and the difference was significant (p = 0.026, Fisher’s exact test). At the final follow-up, 97% of patients (37/38 patients) in the TPD group and 90% of patients (54/60 patients) in the BP group achieved radiographic union (p = 0.243, Fisher’s exact test). Multiple logistic regression analyses were conducted using stepwise regression to adjust for heterogeneity (age, gender,
fracture level, bone mineral density, pre-existing vertebral fracture, medication used, posterior wall fracture, and prior bisphosphonate use) between the two groups (Table 2). Regarding TPD versus BP use, the adjusted odds ratio for union at six months after treatment was 8.15 (95% C.I.: 2.02–43.33). Fracture site surgical interventions were not required in the TPD group, whereas two patients in the BP group eventually underwent surgical treatment. One patient was treated by balloon kyphoplasty for symptomatic non-union, and the other underwent posterior decompression and fusion for vertebral collapse with a neurological deficit.

The change of mid-vertebral body height was 4.4 mm in the TPD group and 3.4 mm in the BP group (p = 0.228, paired t-test) (Fig. 4). The change of local kyphosis was 4.6° in the TPD group and 3.8° in the BP group (p = 0.495, paired t-test) (Fig. 3). Progression of vertebral deformity (>15% loss of vertebral body height or >10° of kyphosis progression) was observed in 66% of the TPD group (25/38 patients) versus 60% of the BP group (36/60 patients), a difference that was not significant (p = 0.670, Fisher’s exact test). The union rate was 84% (21/25) in the TPD group, and 61% (22/36) in the BP group (p = 0.086, Fisher’s exact test). Multivariate logistic regression analysis using the stepwise method showed that teriparatide significantly was associated with an increased union rate; the adjusted odds ratio was 7.80 (95% C.I.: 1.41–70.35) in cases with vertebral deformity progression.

Union at six months was achieved in 61% (11/18 patients) of those with prior bisphosphonate use (past-BP) and in 71% (30/42 patients) of those without prior BP use in the BP group (p = 0.086, Fisher’s exact test). Multivariate logistic regression analysis using the stepwise method showed that teriparatide significantly was associated with an increased union rate; the adjusted odds ratio was 7.80 (95% C.I.: 1.41–70.35) in cases with vertebral deformity progression.

Union at six months was achieved in 61% (11/18 patients) of those with prior bisphosphonate use (past-BP) and in 71% (30/42 patients) of those without prior BP use in the BP group (p = 0.547, Fisher’s exact test). The union rate was 86% (18/21 patients) among those with prior BP use and 94% (16/17 patients) among those without prior BP use in the TPD group (p = 0.613, Fisher’s exact test). The union rate at final follow-up was 89% (16/18 patients) among those with prior BP use and 90% (38/42 patients) among those without prior BP use in the BP group (p = 1.000, Fisher’s exact test). Union

Table 2 Multivariable logistic regression analysis using stepwise method for union status at 6 months after treatment

| Factors                              | p-value | Adjusted odds ratio (95% CI) |
|--------------------------------------|---------|-----------------------------|
| Age (<80 vs. ≥80 years)              | 0.205   | 2.21 (0.65 – 8.11)          |
| Gender                               | p > 0.25|                             |
| Fracture level (TL vs. non-TL)       | 0.001*  | 11.67 (2.48 – 83.17)        |
| BMD at lumbar spine (≤−2.5 vs. >−2.5 SD) | 0.001*  | 11.68 (2.48 – 83.17)        |
| Pre-existing VCF                     | p > 0.25|                             |
| Posterior wall fracture              | 0.001*  | 8.53 (2.25 – 42.23)         |
| Past bisphosphonate use              | 0.019*  | 4.86 (1.29 – 22.09)         |
| Pharmaceutical agents (TPD vs. BP)   | 0.002*  | 8.15 (2.02 – 43.33)         |

* p < 0.05, 95% CI: 95% confidence interval, BMD: bone mineral density, SD: standard deviation, VCF: vertebral compression fracture, TL: thoracolumbar spine (T11-L2), non-TL: non-thoracolumbar spine (T5-T10 or L3-L5), TPD: teriparatide, BP: bisphosphonate

Fig. 2 Kaplan-Meier curves for time-to-union in the TPD group versus the BP group. The Kaplan-Meier curve showed the time course of union in the TPD group and the BP group (p < 0.001, log-rank test). The thin black arrow shows the end of follow-up with non-union, and the bold white arrow indicates the end of follow-up due to surgical intervention. The union rate was 89% in the TPD group and 68% in the BP group by six months after treatment (p = 0.026, Fisher’s exact test). At the final follow-up, 97% of those in the TPD group and 90% of those in the BP group achieved a stable union (p = 0.243, Fisher’s exact test).
occurred in 95% (20/21 patients) of those with prior BP use and in 100% (17/17 patients) of those without prior BP use in the TPD group (p = 1.000, Fisher’s exact test). Time-to-union significantly differed between the TPD group without prior BP use (3.4 ± 1.8 months) and the BP group without prior BP use (7.7 ± 1.1 months) (p = 0.042, t-test). Whereas prior bisphosphonate use tended to delay the time-to-union in the TPD group (3.4 ± 0.6 to 4.8 ± 0.5 months) (p = 0.070, t-test), it did not affect the time-to-union in the BP group (7.8 ± 1.4 to 8.3 ± 2.1 months) (p = 0.827) (Table 3). The duration of prior-BP use did not show a correlation with the OVCF time-to-union (Fig. 4).

Discussion
The current study demonstrated that the radiographic union rate by six months after treatment was significantly higher in the teriparatide group (89%) than in the bisphosphonate group (68%), with an adjusted odds ratio of 8.15 (95% C.I.: 2.02–43.33). The time-to-union was significantly less in the teriparatide group (3.4 ± 1.8 months) and the BP group without prior BP use (7.7 ± 1.1 months) (p = 0.042, t-test). Whereas prior bisphosphonate use tended to delay the time-to-union in the TPD group (3.4 ± 0.6 to 4.8 ± 0.5 months) (p = 0.070, t-test), it did not affect the time-to-union in the BP group (7.8 ± 1.4 to 8.3 ± 2.1 months) (p = 0.827) (Table 3). The duration of prior-BP use did not show a correlation with the OVCF time-to-union (Fig. 4).

Table 3 Effect of bisphosphonate use prior to osteoporotic vertebral fracture

|                   | With prior BP | Without prior BP | p-value |
|-------------------|---------------|------------------|--------|
| **BP group**      |               |                  |        |
| Union rate at 6 months | 61.0% (11/18) | 71.4% (30/42)    | 0.547  |
| Union rate at final follow-up | 88.9% (16/18) | 90.5% (38/42)    | 1.000  |
| Time-to-union (months) | 8.3 ± 2.1    | 7.8 ± 1.4        | 0.827  |

(95% C.I.: 4.2 – 12.5) (95% C.I.: 5.0 – 10.5)

| **TPD group**     |               |                  |        |
| Union rate at 6 months | 85.7% (18/21) | 94.1% (16/17)    | 0.613  |
| Union rate at final follow-up | 95.2% (20/21) | 100% (17/17)     | 1.000  |
| Time-to-union (months) | 4.8 ± 0.5    | 3.4 ± 0.6        | 0.070  |

(95% C.I.: 3.8 – 5.8) (95% C.I.: 2.3 – 4.5)

p-value
|                   |               |                  |        |
| Union rate at 6 months | 0.141        | 0.084            |        |
| Union rate at final follow-up | 0.586       | 0.314            |        |
| Time-to-union         | 0.115         | 0.042            |        |

*p < 0.05, With prior BP: with bisphosphonate use prior to the time of osteoporotic vertebral fracture, Without prior BP: without bisphosphonate use prior to the time of osteoporotic vertebral fracture
This higher union rate despite the progression of vertebral deformity suggests that teriparatide use may help reduce the need for surgical intervention for OVCF. Previous randomized controlled trials demonstrated that teriparatide accelerated fracture healing. Aspenberg et al. conducted a prospective, randomized, double-blind study of 102 postmenopausal women with distal radius fractures, and showed that the time to cortical bridging was significantly shorter in the once-daily 20-microgram teriparatide group than in the placebo control group [16]. Peichl et al. also demonstrated in their randomized controlled trial of 65 patients with osteoporotic pubic bone fractures that a once-daily injection of PTH 1–84 accelerated healing compared with treatment with vitamin D with calcium [17]. Additionally, several clinical cases were reported to show successful repair of non-union in sternum fractures [18] and dens fractures [19].

According to population-based epidemiologic studies, the prevalence of postmenopausal osteoporosis is approximately 30 to 45% in women aged 70 years [20, 21] and 40–45% in those aged 80 years [21, 22]. Osteoporotic fractures and related problems impact the quality of life in the older adult population. Failure of fracture healing in OVCF leads to intractable back pain associated with non-union [9, 13]. Patients with symptomatic vertebral non-union frequently require surgical interventions, including balloon kyphoplasty or spinal reconstruction. Furthermore, once non-union advances to osteonecrosis, the collapsed vertebrae cause a progressive kyphotic deformity and severe neural tissue compression with neurological deficits [8, 9, 23]. These pathologies can be managed only through major spinal reconstruction using instrumentation [24, 25]. Thus, the utmost priority in the treatment of OVCF is to prevent vertebral non-union and osteonecrosis.

In the current study, the risk factors for non-union were thoracolumbar fracture, decreased bone mineral density, posterior wall fracture, and prior bisphosphonate use. Vertebral non-union typically has been reported to occur mainly in the thoracolumbar zone [9, 13]. This phenomenon occurs due to the high stresses in this region generated by the transition from the rigid thoracic spine to the flexible lumbar spine along with the anterior element force transmission from the kyphotic thoracic spine to the relatively neutral thoracolumbar junction. Bone mineral density was negatively correlated with the intravertebral vacuum occurrence rate [26, 27]. Posterior wall fracture was reported to be a risk factor for progression of vertebral collapse [15, 28]. These factors might be considered related to the vulnerability of the small blood-supplying arteries in the vertebral bodies. Interruption of the blood supply and insufficient bone marrow neovascularization are the likely causes of avascular necrosis of the vertebral body, which may result in vertebral non-union [10, 13, 29]. Once vertebral necrosis occurs, union is difficult to achieve in the presence of a vertebral cleft. Peripheral bridging bone formation around an OVCF with vertebral clefting was often observed using teriparatide, as shown in Fig. 1. With peripheral bridging bone cross-linkage along the vertebral edges, the stability of the collapsed vertebra was recovered. Teriparatide was reported to
promote ossification of the spinal ligaments [30] and to accelerate hyperplastic bone formation around vertebral fractures in a case of diffuse idiopathic skeletal hyperostosis [31]. In the current study, teriparatide significantly affected union in cases of vertebral deformity progression (adjusted odds ratio 7.80). Moreover, prior bisphosphonate use was an independent risk factor for non-union at six months. The substantial suppression of osteoclast activity with BP use might be implicated in the current results. Prior bisphosphonate use was associated with delayed union, particularly with teriparatide use. However, the duration of prior bisphosphonate use did not correlate with the time-to-union and the union rate of OVCF at the final follow-up. An explanation for this finding might be that bone metabolism after introducing the bisphosphonate may subside to a constant value by three months, with maintenance of that rate thereafter. Nenonen showed a rapid decrease and persistent change of bone metabolic markers after introducing a bisphosphonate [32]. Once the metabolism was suppressed by the bisphosphonate, bone formation would not ensue with the use of teriparatide.

Both the teriparatide and bisphosphonate groups were similar regarding the inhibition of vertebral deformity progression. Fractured vertebrae require several months to achieve adequate mechanical strength and a stable union. Angular kyphosis develops within several weeks or months after injury [33, 34]. Although teriparatide has the potential to increase bone mineral density and vertebral body strength [35, 36], vertebral deformity might progress before the medication has elicited its effects on vertebral mechanical strength.

Several limitations of the current study should be addressed. This is a retrospective comparative study that included different sample sizes and demographics between the two treatment groups. The inter-group difference in the ratio of prior bisphosphonate use was a potential source of selection bias in this study. To adjust for heterogeneity between the two treatment groups, we used multiple logistic regression analysis. The biological aspects of fracture healing should be examined prospectively using bone metabolic markers, vitamin D, and parathyroid hormone level status to determine whether the state of bone turnover was comparable between the TPD group and the BP group at baseline and to probe whether treatment affected bone turnover in these patients. Due to the nature of retrospective investigation, serum bone markers could be collected only in a very limited number of patients. In this retrospective study, the follow-up duration after three months following treatment differed for each doctor. Considering the follow-up duration differences, we showed the union rate on the Kaplan-Meier survival curve as the time course of vertebral union for each medication. An MRI study might help assess the early phase of fracture healing.

**Conclusions**
This retrospective study suggests that teriparatide may potentially enhance fracture healing and improve the union rate in OVCF.

**Abbreviations**
95% CI: 95% confidence interval; BMD: Bone mineral density; DXA: Dual-energy X-ray absorptiometry; GFR: Glomerular filtration rate; non-TL: Non-thoracolumbar spine (T5-T10 or L3-L5); OVCF: Osteoporotic vertebral compression fracture; Prior-BP: Bisphosphonate use prior to osteoporotic vertebral compression fracture; PTH: Parathyroid hormone; SD: Standard deviation; TL: Thoracolumbar spine (T11-L2); TPD: Teriparatide; YAM: Young adult mean value

**Acknowledgments**
We would like to express our sincere gratitude to our hospital colleagues, nurses, physical therapists, X-ray technicians, pharmacists, and clerks who provided care to the patients. As always, we thank our families for supporting our efforts.

**Availability of data and materials**
All data supporting our findings are contained within the manuscript.

**Authors’ contributions**
AI was involved in the design of the study, performed the clinical assessment, analyzed the data, and drafted the manuscript. MK, FO, and TH contributed to the clinical assessment. MK involved in the study design, assisted with data interpretation, and revised manuscript for intellectual content. NI revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

**Competing interests**
The authors declare that they have no competing interests. The authors do not have any commercial relationships that could be constructed as biased or inappropriate.

**Consent for publication**
Not applicable.

**Ethics approval and consent to participate**
This retrospective study was approved by the Institutional Review Board of the Hakodate Central General Hospital. The approval number was 2013–5. Informed consent was not obtained from the participants due to the IRB provision for the retrospective study.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**
1. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action - alendronate localization in Rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095–105.
2. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res. 1996;14(1):74–9.
3. Xue D. Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials. J Orthop Surg Res. 2014;9(1):45.
4. Molvik HH. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26(4):1251–60.
5. Dempster DW, Cosman F, Parisen M, Shen V, Lindsay R. Anabolic actions of parathyroid-hormone on bone. Endocr Rev. 1993;14(6):690–709.
6. Jilka RL, Weinstein RS, Belardo T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104(4):439–46.
7. Dobbs H, Turner RT. Evidence that intermittent treatment with parathyroid-hormone increases bone-formation in adult-rats by activation of bone lining cells. Endocrinology. 1995;136(8):3632–8.
8. Hoshino M, Nakamura H, Terai H, Tsuji T, Nabeto M, Namikawa T, Matsumura A, Suzuki A, Takayama K, Takaoa K. Factors affecting neurological deficits and intractable back pain in patients with insufficient bone union following osteoporotic vertebral fracture. Eur Spine J. 2009;18(9):1279–86.
9. Pappou IP, Papadopoulos EC, Swanston AN, Camminisa FP, Girardi FP. Osteoporotic vertebral fractures and collapse with intravertebral vacuum sign (Kummel’s disease). Orthopedics. 2008;31(1):61–6.
10. Ito YY. Pathogenesis and diagnosis of delayed vertebral collapse resulting from osteoporotic spinal fracture. Spine J. 2002;2(10):101–6.
11. Heinl PF. The current treatment—a survey of osteoporotic fracture treatment. Osteoporotic spine fractures: the spine surgeon’s perspective. Osteoporos Int. 2005;16 Suppl 2: S2592.
12. Wardlaw DD. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FRE): a randomised controlled trial. Lancet. 2009;373(9668):1016–24.
13. He DD. Pathogenesis of the intravertebral vacuum of Kümmell disease. Exp Ther Med. 2016;12(2):879–82.
14. Nakamura T. Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006. Clin Calcium. 2007;17(7):1022–8.
15. Ha KYK. Risk factors affecting progressive collapse of acute osteoporotic spinal fractures. Osteoporos Int. 2013;24(4):1207–13.
16. Aspenberg P, Genant HK, Johansson T, Nino AJ, see K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14.
17. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93A(7):1583–7.
18. Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos Int. 2010;21(6):1059–63.
19. Rubery PT, Bukata SV. Teriparatide May accelerate healing in delayed unions of type III odontoid fractures a report of 3 cases. J Spinal Disord Tech. 2010;23(2):151–5.
20. Adami SS. The effect of age, weight, and lifestyle factors on calcaneal quantitative ultrasound: the ESOPO study. Osteoporos Int. 2003;14(3):198.
21. Melton LJL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129(5):1000.
22. Fujivara SS. Epidemiology of osteoporosis in Japan. J Bone Miner Metab. 2005;23(Suppl):S11–3.
23. Heggeness MHH. Spine fracture with neurological deficit in osteoporosis. Osteoporos Int. 1995;5(4):275–21.
24. Kaneda K, Asano S, Hashimoto T, Sato S, Fujida M. The treatment of osteoporotic posttraumatic vertebral collapse using the kaneda device and a bioactive ceramic vertebral prosthesis. Spine. 1992;17(8):S295–303.
25. Kanayama M, Ishida T, Hashimoto T, Shigenobu K, Togawa D, Oha F, Kaneda K. Role of major spine surgery using kaneda anterior instrumentation for osteoporotic vertebral collapse. J Spinal Disord Tech. 2010;23(1):53–6.
26. Wu AM. Vertebral compression fracture with intravertebral vacuum cleft sign: pathogenesis, image, and surgical intervention. Asian spine J. 2013;7(2):148–55.
27. Stäbler CC. Intravertebral vacuum phenomenon following fractures: CT study on frequency and etiology. J Comput Assist Tomogr. 1999;23(6):876–80.
28. Hayashi TT. Morphology of the injured posterior wall causing spinal canal encroachment in osteoporotic vertebral fractures. Spine J. 2016;16(8):946–50.
29. Freedman BA. Kummel disease: a not-so-rare complication of osteoporotic vertebral compression fractures. J Am Board Fam Med. 2009;22(1):75–8.
30. Hamano HH. Teriparatide improves trabecular osteoporosis but simultaneously promotes ankylosis of the spine in the Twy mouse model for diffuse idiopathic skeletal hyperostosis. Calcif Tissue Int. 2016;98(2):140–8.